Publications by authors named "David Millson"

Claim this Profile
S
Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study.
Yoshiya Tanaka, David Millson, Shigeru Iwata, Shingo Nakayamada

Rheumatology (Oxford)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies.
Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey

Clin Pharmacol Drug Dev· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey

Drugs R D· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey

Clin Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Paul Martin, Stuart Oliver, Michael Gillen, Thomas Marbury, David Millson

Clin Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Michael E Weinblatt, Mark C Genovese, Meilien Ho, Sally Hollis, Krystyna Rosiak-Jedrychowicz, David S Millson

Arthritis Rheumatol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnic differences in risks of adverse reactions: is personalised drug treatment better with pharmacokinetic modelling?
David S Millson

BMJ· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are consenters representative of a target population?
David S Millson

BMJ· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substance misuse and psychiatric illness: prospective observational study using the general practice research database.
Martin Frisher, Ilana Crome, John Macleod, David Millson, Peter Croft

J Epidemiol Community Health· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A method to determine if consenters to population surveys are representative of the target study population.
Helen F Boardman, Elaine Thomas, Helen Ogden, David S Millson, Peter R Croft

J Public Health (Oxf)· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychological, sleep, lifestyle, and comorbid associations with headache.
Helen F Boardman, Elaine Thomas, David S Millson, P R Croft

Headache· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year follow-up of headache in an adult general population.
Helen F Boardman, Elaine Thomas, David S Millson, Peter R Croft

Headache· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of comorbid psychiatric illness and substance misuse in primary care in England and Wales.
Martin Frisher, Juliet Collins, David Millson, Ilana Crome, Peter Croft

J Epidemiol Community Health· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What has happened to antimicrobial usage in primary care in the United Kingdom since the SMAC report? - description of trends in antimicrobial usage using the General Practice Research Database.
Gillian E Smith, Sue Smith, Heath Heatlie, James N R Bashford, Jeremy Hawker, David Millson

J Public Health (Oxf)· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
Darren M Ashcroft, David Millson

Pharmacoepidemiol Drug Saf· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profile of the triptans.
Stewart J Tepper, David Millson

Expert Opin Drug Saf· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study.
Mark Sculpher, David Millson, David Meddis, Lynne Poole

Pharmacoeconomics· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis